Symptom Monitoring & Systematic Assessment and Reporting System in Young Survivors (SyMon-SAYS) for Malignancies

More investigations are needed to assess whether the prognosis varies according to the cancer type by investigating the risk factors and risk factor-related gene polymorphisms.

There is a growing consensus among health care providers that the treatment of malignancies has not been improved over centuries. Nevertheless, many malignant diseases can be cured by adjuvant treatment. Some malignancies have been cured by the advancement of treatment techniques. Patients who do not have malignancies can still benefit from treatment.

It is quite common and the treatment of lymphoma, [breast cancer](https://www.withpower.com/clinical-trials/breast-cancer), melanoma, cancer of the gastrointestinal tract and brain have a high rate of survival. However, the treatment of cancer is highly dependent on the specific patient.

Approximately 80,000 people develop leukemia in the United States each year, of whom approximately 65,000 will achieve hematologic responses to treatment with imatinib, the first targeted therapy. Although more than 20,000 new cases of Burkitt's lymphoma are reported per year, the 5-year survival rate of newly diagnosed patients is more than 100%.

There is very strong genetic risk for developing cancers from a number of different genes (cancers). It appears that the risk of developing cancer increases with ageing. Cancers of two types—benign tumours and malignant tumours, especially lung cancer—occur at high rates (10% and 5% respectively). They both arise because of uncontrolled growth in the body, which is caused by an uncontrolled DNA-making process ( cell signalling pathways). Many of the signalling pathways that control the DNA-making process are the same for both benign and malignant cancers. Both types seem to arise through a number of common pathways, and the two types appear to share the same underlying biology (cell signalling pathways and DNA making processes).

Clinical symptoms of malignancy vary widely among patients with hematologic malignancies. These include anemia, leukocytosis, thrombocytosis, and fever. They can be caused by the leukemitotic effect of treatment, disseminated intravascular coagulation (DIC), leukemia, myelofibrosis, and metastatic hematological malignancies. Signs of malignancy that may be present without suspicion include a positive CBC, and a positive urinalysis or CAST.

Malignancies are cancers that form in the body and cause an uncontrolled growth of cells. They may be benign at the start or become malignant after the start. malignancies of hematological, lymphoid, and mesothelial origin may occur. They have become a leading cause of death in the United States. Most commonly occurring forms of cancer in adults are lung cancer and colon, pancreas, prostate, breast, and cervical. Cancer can be detected and diagnosed using imaging, blood tests, or biopsy. In many cases, it is determined by tissue typing. The number of new cases of lung cancer is about 40,900.

The young survivors' group requires a structured systematic symptom monitoring and reporting system during follow-up, a medical summary document and an integrated care plan for any subsequent problems. Young survivors often have problems with coping skills that can help them to cope with adverse experiences to promote recovery.

There are many challenges facing young survivors who are being assessed in this setting for potential clinical use, for a variety of reasons. We suggest that there are a number of ways that healthcare service providers could use Symon-says® to identify and monitor these risks that may compromise their young survivors' post-treatment health.

The environmental risk factors in malignancies, including tobacco and alcohol, are more powerful on a global (population-wide) scale than the genetic factors that are most closely related to a particular individual's risk for some specific individual cancers. The specific cancer incidence attributable to these environmental factors is, however, quite substantial.

There have been many breakthrough discoveries for treating malignancies. It is difficult to determine what will actually become standard treatment because the data from clinical trials are often not adequate to make solid recommendations. Clinical trials are often performed on small numbers of patients and have short durations. In many cases, most patients do not receive the therapy due to side effects or lack of effectiveness. More trials are needed so that drugs with improved side effects and improved effectiveness can be put into use.